Michael Jaramillo, Author at Renibus Therapeutics

Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery

Renibus Announces First Patient Enrolled in PROTECT Phase 3 [...]

Michael Jaramillo2023-10-31T07:29:09-07:00October 25, 2023|

Renibus Therapeutics Announces Participation at Upcoming Investor Conferences SOUTHLAKE, [...]

Michael Jaramillo2023-10-10T13:05:04-07:00October 10, 2023|

Renibus Therapeutics Announces Final Close of Upsized Series B [...]

Michael Jaramillo2023-09-12T04:59:59-07:00September 12, 2023|

Renibus Presents Phase 2 Results on RBT-1, a First-in-Class [...]

Michael Jaramillo2023-09-11T05:00:14-07:00September 11, 2023|

Renibus Therapeutics Announces $47 Million Financing to Advance Lead [...]

Michael Jaramillo2023-07-17T13:56:08-07:00July 18, 2023|

Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for [...]

Michael Jaramillo2023-07-10T14:54:59-07:00July 11, 2023|

Renibus Reports Positive Final Results from Phase 2 Study [...]

Michael Jaramillo2023-05-07T07:54:11-07:00May 5, 2023|

Renibus Therapeutics Announces Presentation at 22nd Annual Needham Virtual [...]

Michael Jaramillo2023-04-05T04:59:52-07:00April 5, 2023|

Renibus Therapeutics Announces Presentation at Oppenheimer 33rd Annual Healthcare [...]

Michael Jaramillo2023-03-07T13:05:09-08:00March 7, 2023|

Renibus Therapeutics Announces Participation in the SVB Securities Global Biopharma [...]

Michael Jaramillo2023-01-30T05:01:59-08:00January 30, 2023|